Semaglutide: Full Research Guide, Protocol & Vendor Pricing

Everything researchers need on semaglutide in one place. This guide covers the chemistry, full mechanism, all major clinical trials, the complete titration protocol, side effect management, reconstitution, and COA-verified vendor pricing. No paywalls, no fluff.

Chemistry & Structure

Semaglutide is a 31-amino acid GLP-1 analogue. Its molecular weight is approximately 4,113 Da. Two structural modifications distinguish it from native GLP-1:

• Position 8: Alanine replaced with α-aminoisobutyric acid (Aib) — prevents DPP-4 enzymatic cleavage, which would otherwise degrade native GLP-1 within minutes
• Position 26: Lysine modified with a C18 fatty diacid via a linker — enables reversible albumin binding, extending plasma half-life to ~7 days and allowing subcutaneous depot formation
• Position 34: Arginine substituted for lysine — prevents attachment of the fatty chain to the wrong residue during synthesis

The result is a molecule that behaves like GLP-1 at receptors but survives long enough in circulation to be dosed once weekly.

Full Mechanism of Action

GLP-1 Receptor Activation

GLP-1 receptors are distributed across multiple tissues: pancreas, brain, heart, gut, kidney, and lung. Semaglutide binds all of these. The primary effects relevant to research are:

• Pancreatic β-cells: Glucose-dependent insulin secretion. No insulin release below ~70 mg/dL blood glucose — this is the safety feature that distinguishes GLP-1 agonists from insulin
• Pancreatic α-cells: Suppression of glucagon, reducing hepatic glucose output
• Hypothalamus/brainstem: Activation of satiety centers; reduced NPY/AgRP signaling (hunger) and increased POMC/CART (satiety). This is the primary driver of appetite suppression
• Gastrointestinal tract: Slowed gastric emptying — food stays in the stomach longer, prolonging satiety signals
• Cardiovascular: Direct cardioprotective effects via GLP-1R on cardiac tissue; reduced inflammation, improved endothelial function

Central vs Peripheral Effects

Research increasingly distinguishes between the peripheral effects (gut slowing, insulin regulation) and the central effects (appetite suppression in the brain). Emerging data suggests the central effects may be more important for weight loss than previously thought — semaglutide appears to cross the blood-brain barrier and act directly on reward circuits, reducing food cravings beyond just satiety.

Complete Clinical Trial Overview

Research Protocol & Titration

The titration schedule below mirrors what was used in the STEP trials and is the standard research reference protocol. Deviating upward faster than this schedule significantly increases GI side effect rates.

Some research protocols hold at 1.0mg as maintenance rather than escalating to 2.4mg. The dose-response relationship is not fully linear — meaningful benefit is seen at 1.0mg, with diminishing marginal returns at higher doses for some subjects.

Reconstitution Guide

Semaglutide for research is supplied as lyophilized (freeze-dried) powder and must be reconstituted before use.

1. Allow the vial to reach room temperature (15–30 min)
2. Draw the desired volume of bacteriostatic water (BAC water) into a syringe
3. Inject BAC water slowly down the inner wall of the vial — do not spray directly onto the powder
4. Gently swirl (do not shake) until fully dissolved — solution should be clear
5. Standard reconstitution: 2mL BAC water per 2mg vial = 1mg/mL concentration
6. Store reconstituted solution refrigerated at 2–8°C; use within 28 days

Side Effect Management

GI Side Effects (Most Common)

Nausea, vomiting, diarrhea, and constipation are the dominant adverse effects and are dose-dependent. Management strategies used in clinical trials:

• Eat smaller meals; avoid high-fat and high-sugar foods around injection day
• Stay hydrated; GI effects increase dehydration risk
• If nausea is persistent, hold at current dose for an additional 4 weeks before escalating
• Ginger (tea or supplements) has been used anecdotally to manage nausea in research contexts

Lean Mass Preservation

STEP trials showed ~38% of weight lost was lean mass in some cohorts. This is the biggest concern for research subjects focused on body composition. Resistance training and high protein intake (≥1.6g/kg bodyweight) appear to be the most effective mitigations in current literature.

Thyroid Considerations

Animal models showed medullary thyroid carcinoma signal at high doses. Human epidemiological data has not confirmed this, but individuals with personal or family history of MEN-2 or medullary thyroid carcinoma are typically excluded from research protocols.

How Semaglutide Compares

Semaglutide has the most real-world safety and efficacy data. Tirzepatide and retatrutide show higher average weight loss in trials but are newer. See the 3-way comparison for full detail.

Current Vendor Pricing